National Academies Will Meet to Guide 'Gene Editing' Research
By Lisa M. Krieger,
San Jose Mercury News
| 05. 18. 2015
Untitled Document
The debate over human "gene editing" has moved onto the national stage with a prestigious institute announcing it will hold an international summit this fall to create voluntary standards to guide the use of the controversial technology, first conceived by UC Berkeley molecular biologist Jennifer Doudna.
The landmark conference, announced Monday by the Washington, D.C.-based National Academy of Sciences and National Academy of Medicine, will gather researchers and other experts to review and explore the scientific, ethical and social implications of the practice, which can "cut and paste" gene sequences.
Called CRISPR, an acronym for "clustered regularly interspaced short palindromic repeats," Doudna's tool creates the prospect of a future with less sickness -- but could alter future generations -- influencing human evolution by changing the genes in reproductive cells.
The decision to hold a summit follows last month's news that Chinese researchers created the first genetically modified humans, altering nonviable embryos to try to fix the gene defect that causes beta thalassemia, a blood disease.
Doudna and colleagues, including Stanford University bioethicist Hank Greely, last month called for...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...